Dr. Wolf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave Ste A502
San Francisco, CA 94143Phone+1 415-353-2421Fax+1 415-353-2545
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1976 - 1978
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1975 - 1976- University of California (San Diego) Medical CenterResidency, Internal Medicine, 1972 - 1974
University of Illinois College of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1973 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
- A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25
Publications & Presentations
PubMed
- Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M Morán-Segura
Blood Cancer Journal. 2024-10-16 - 5 citationsCD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.Guy Ledergor, Zenghua Fan, Kai Wu, Elizabeth McCarthy, Axel Hyrenius-Wittsten
Blood Advances. 2024-07-09 - 8 citationsSalvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin
Blood Advances. 2024-05-14
Abstracts/Posters
- Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and BiologyJeffrey L. Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Germline Variation Predicts Treatment Response in Multiple MyelomaJeffrey Lee Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
